Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:43 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Powder Clear all
Recruiting Phase 2 Interventional

VENTURI (VENTilation Using Respiratory Imaging)

NCT07282886
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 3, 2026, 4:43 AM EST
Terminated Phase 1 Interventional

Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma

NCT02163356
View directory record Official record
Conditions
Recurrent Neuroblastoma, Neuroblastoma
Interventions
Fenretinide/LXS Oral Powder, Ketoconazole, Vincristine
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • Dallas, Texas • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Nov 3, 2026, 4:43 AM EST
Terminated Phase 2 Interventional Results available

Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)

NCT01009294
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Ataluren, Chronic Corticosteroid Therapy
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
7 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Mechanisms of Asthma

NCT00595153
View directory record Official record
Conditions
Asthma
Interventions
Pulmicort
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Nov 3, 2026, 4:43 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability

NCT05493553
View directory record Official record
Conditions
Healthy, Impaired Glucose Tolerance
Interventions
Dietary supplement regimen, Dietary supplement and intermittent fasting regimen
Dietary Supplement · Other
Lead sponsor
Unicity International, Inc.
Industry
Eligibility
30 Years to 69 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

NCT01686633
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate/ Vilanterol 200/25 mcg, Fluticasone Furoate/ Vilanterol 100/25 mcg, Fluticasone Furoate 100 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
37
States / cities
Little Rock, Arkansas • Huntington Beach, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 1 Interventional

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

NCT00602693
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
umbilical cord blood transplantation, Allopurinol, fludarabine phosphate, Cyclophosphamide, Total body irradiation, Treg infusion, Sirolimus
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Nov 3, 2026, 4:43 AM EST
Terminated Phase 3 Interventional Results available

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

NCT00354432
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Nov 3, 2026, 4:43 AM EST
Terminated Phase 3 Interventional Results available

Open-Label Extension of Voxelotor

NCT04188509
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

NCT01404572
View directory record Official record
Conditions
HIV
Interventions
Atazanavir (current formulation), Atazanavir, powder for oral use 1 (POU1), Atazanavir (POU2)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Nov 3, 2026, 4:43 AM EST
Recruiting Phase 2 Interventional

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

NCT04665037
View directory record Official record
Conditions
Invasive Fungal Infection
Interventions
Posaconazole IV 6 mg/kg, Posaconazole PFS 6 mg/kg
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

NCT01691547
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC /VI, UMEC, VI, FF
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Nov 3, 2026, 4:43 AM EST
Terminated Phase 1 Interventional

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

NCT02235740
View directory record Official record
Conditions
Cancer
Interventions
Afuresertib, Carfilzomib
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Nov 3, 2026, 4:43 AM EST
Completed Not applicable Interventional Results available

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

NCT01113385
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Interventions
D-Galactose
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 3 Interventional Results available

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

NCT02517021
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Santa Monica, California • Whittier, California • Grand Junction, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Nov 3, 2026, 4:43 AM EST
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Leucine for Depression Study (L-DEP)

NCT03557684
View directory record Official record
Conditions
Depression
Interventions
leucine, PO placebo, lipopolysaccharide (LPS), IV placebo
Dietary Supplement · Other · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

NCT02969408
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
44
States / cities
Litchfield Park, Arizona • Bakersfield, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 3, 2026, 4:43 AM EST
Terminated Phase 1 Interventional

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

NCT04702425
View directory record Official record
Conditions
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
Interventions
VOB560, MIK665
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 1Phase 2 Interventional

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

NCT02956317
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
STP705, Placebo
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

NCT05628740
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]
Drug
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

NCT04594213
View directory record Official record
Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Encino, California • Newport Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 3 Interventional

A Trial of CM-AT in Children With Autism- Open Label Extension Study

NCT00912691
View directory record Official record
Conditions
Autism
Interventions
CM-AT
Drug
Lead sponsor
Curemark
Industry
Eligibility
9 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
19
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Nov 3, 2026, 4:43 AM EST
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

NCT03901482
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebos
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
117
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Nov 3, 2026, 4:43 AM EST
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

NCT03217838
View directory record Official record
Conditions
Acute Myeloid Leukaemia
Interventions
AZD2811, Azacitidine, Venetoclax
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Nov 3, 2026, 4:43 AM EST